Chlorodeoxyadenosine : An Effective New Agent for the Treatment of Chronic Lymphocytic Leukemia

2-Chlorodeoxyadenosine, a new lymphocyte-selective. anti-neoplastic drug was administered to 1 8 patients with advanced chronic lymphocytic leukemia of B-cell origin. All patients were resistant to conventional treatment. A total of 44 courses of 2-chlorodeoxyadenosine were completed with minimal toxicity. An overall response rate of 55% was achieved with four of 1 8 patients demonstrating partial response and six of 1 8 patients experiencing clinical improvement. Only minor bone marrow suppression occurred during administration of the drug. indicating a high degree of lymphocyte selectivity. Reduction of lym-

[1]  M. O’connell,et al.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). , 1987, The New England journal of medicine.

[2]  H. Kantarjian,et al.  Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. , 1987, Blood.

[3]  M. Grever,et al.  Low-dose deoxycoformycin in lymphoid malignancy. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Carson,et al.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. , 1985, The Journal of clinical investigation.

[5]  D. Carson,et al.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Yu,et al.  Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes , 1983 .

[7]  R. Dillman,et al.  Chronic lymphocytic leukemia and other chronic lymphoid proliferations: surface marker phenotypes and clinical correlations. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[9]  H. Thaler,et al.  Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). , 1982, Blood.

[10]  D. Catovsky,et al.  Characterization of B-cell leukemias: a tentative immunomorphological scheme. , 1981, Blood.

[11]  E. Montserrat,et al.  Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System , 1981 .

[12]  H. Birnboim,et al.  Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. , 1981, Cancer research.

[13]  R. K. Robins,et al.  Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Conley,et al.  Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. , 1980, Medicine.

[15]  J. Dausset,et al.  An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells , 1980, The Journal of experimental medicine.

[16]  L. Peterson,et al.  Relationship of Clinical Staging and Lymphocyte Morphology to Survival in Chronic Lymphocytic Leukaemia , 1980, British journal of haematology.

[17]  R. Silver,et al.  Guidelines for protocol studies in chronic lymphocytic leukemia , 1978, American journal of hematology.

[18]  K. Rai,et al.  Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. , 1977, Blood.

[19]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[20]  B. Hoerni,et al.  [Treatment of chronic lymphocytic leukemia]. , 1971, Bordeaux medical.